周四，Morgan Stanley将Centessa Pharmaceuticals (NASDAQ:CNTA)的评级从持平上调至增持，并将目标价从之前的11美元大幅提高至26美元。这一估值变化是基于该公司ORX750研究的中期Phase 1结果。研究表明，该药物进入Phase 2开发阶段的轨迹明确，并暗示作为嗜睡症治疗方法的orexin 2受体的风险概况有所降低。

Centessa Pharmaceuticals (NASDAQ:CNTA) was upgraded to Overweight from Equal-weight at Morgan Stanley as the brokerage ...

A small, early study produced what one analyst called “highly compelling” results that lifted the company’s shares by as much as 15% Tuesday.

Centessa Pharmaceuticals (CNTA) has received a new Buy rating, initiated by B.Riley Financial analyst, Mayank Mamtani. Mayank Mamtani has given ...

The effects of sleep deprivation on cognitive function may be reversed by treatment with a compound called orexin-A, which occurs naturally in the mammalian brain. The new research was done with ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

Dr Bianca Ogden and Hashan De Silva share the companies and trials they find interesting in the constantly innovating biotech ...

Learn more about whether Arcellx Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on AAII's A+ Investor ...

Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist ...

Learn more about whether ACADIA Pharmaceuticals Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on ...

Analyst David Risinger of Leerink Partners maintained a Buy rating on Centessa Pharmaceuticals (CNTA – Research Report), boosting the ...

Further research into neuropeptides such as corticotropin-releasing hormone (CRH), orexin, galanin, and cocaine- and amphetamine-regulated transcript (CART) may, however, help clarify the workings ...